Gilead and Assembly Biosciences partner to develop next-gen therapeutics
Gilead Sciences has entered into a 12-year partnership with Assembly Biosciences, a biotechnology company developing antiviral therapeutics targeting serious viral diseases. The partnership, announced 17 October, aims to advance the research and development of novel antiviral therapies, with an initial focus on Assembly Bio’s established areas of herpesviruses, hepatitis B virus (HBV) and hepatitis D […]
